Mao Zhang Named to Harvard Appartus Board of Directors

Harvard Apparatus Regenerative Technology Inc. has appointed Mao Zhang as an independent board director, adding strength in business innovation, strategy, and finance to the governing body.

“We are pleased to welcome Mao Zhang to the Harvard Apparatus Regenerative Technology Board,” Harvard Apparatus Board Chairman Jerry He said. “Mao’s deep business and investment experience will be instrumental in helping the company to pursue the mission to serve the unmet patient needs. His appointment will be invaluable to Harvard Apparatus Regenerative Technology at a time of significant opportunity and growth.”
 
Zhang is the founder and CEO of StellarS Capital, a multi-billion-dollar alternative asset management firm established in 2016. He has more than 15 years of experience in financial markets including hedge fund and private equity. He began his career with Magnetar Capital in 2007, leading its Asian business.

Zhang earned a bachelor of science degree from the University of Pennsylvania.
 
“I am very pleased to be joining the Board of Directors for Harvard Apparatus Regenerative Technology at this exciting stage of its clinical development,” Zhang stated. “Harvard Apparatus Regenerative Technology is developing promising novel cell therapies with the potential to change and extend the lives of patients with regenerated organs. I look forward to helping Harvard Apparatus Regenerative Technology reach its financial and strategic objectives.”
 
Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its technology is based on the firm’s proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The company believes the platform represents a next-generation solution for restoring organ function because it allows the patient to regenerate his/her own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient’s own organs, or permanent artificial implants. Harvard Apparatus conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure showed the technology successfully regenerated esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube. 

Harvard Appartus has 15 issued U.S. patents, two issued in China, one issued in Japan, two issued in Europe, two U.S. orphan-drug designations which can provide seven years of market exclusivity in the U.S. market after market approval from the U.S. Food and Drug Administration, and one EMA orphan drug designation, which can provide ten years of market exclusivity in the European market after market approval from the EMA.